Pharmaceuticals(36)
-
Higher Efficiency of CRISPR Gene Editing Using Chimeric Cas9 (No. T4-1930)
CRISPR-Cas9 is a powerful tool for genome editing, widely used for basic research and the development of treatments for genetic diseases. However, its efficiency is currently limited. ... Read more6024 -
Protein Based Treatment for Duchene Muscular Dystrophy and Cancer (No. T4-1913)
Duchenne muscular dystrophy (DMD) is a disease that affects approximately 1 in 3,500 boys with a life expectancy of ~26 years. ... Read more6026 -
Preventing Biofilm Formation by Enzyme Inhibitors (No. T4-1893)
Biofilm is a complex colony of bacteria, which are attached together by extracellular polymeric substance. This setting provides the bacteria protection against environmental factors, improves their surface attachment, and plays a major role in resistance to treatment. ... Read more5731 -
Universal CAR-Ts for Treating Cancer (No. T4-1884)
Chimeric Antigen Receptor T-Cells (CAR-Ts) are one of the revolutionary technologies of the twenty-first century, invented by Prof. Zelig Eshhar at the Weizmann Institute of Science. ... Read more
Zelig Eshhar
Faculty of Biology5722 -
A Platform for Identifying Specific Autophagy Inhibitors for Cancer (No. T4-1883)
Autophagy plays a vital role in the survival of many solid tumors, often leading to drug resistance in chemotherapy and targeted treatments. Prof. ... Read more18497 -
Targeting Novel Regulator for Improved Hematopoietic Stem Cells Generation (No. T4-1874)
A potential method of generating hematopoietic stem cells for transplantation by inhibiting CD74. ... Read more5716 -
Microbiome-Based Prediction, Diagnosis, and Treatment of Relapsing Obesity (No. T4-1805)
A novel method for analyzing the likelihood of weight regain following a weight loss program and maintaining target body weight, based on gut microbiome analysis. ... Read more5659 -
Treating Drug-Resistant Lung Cancer Using a Combination of Antibodies (No. T4-1774)
A novel method to treat tyrosine kinase inhibitor (TKI) resistant cancer by using a combination of three antibodies that target EGFR (ERBB1), HER2 (ERBB2), and HER3 (ERBB3) receptors. ... Read more5635 -
Treatment of Heart Failure by Inducing Cardiomyocyte Proliferation (No. T4-1752)
Regulating ErbB2 signaling in cardiomyocytes (CM) as novel treatment for heart diseases by inducing regeneration of cardiac tissue. ... Read more5623 -
Preventing Infections Using Lipid Based Molecules (No. T4-1673)
Sphingosine (SPH), a natural bactericidal agent which acts as a part of the human innate immune system in the skin, was found to be an effective treatment and prophylaxis for bacterial lung infections in cystic fibrosis (CF) mice. ... Read more5584
Pages
